CMS Rejects HHS Call For Off-Label Avastin Endorsement
Medicare administrators are shooting down recommendations in a government study released Monday that adds fresh ammunition to claims off-label use of cancer drug Avastin for eye disease could save taxpayers billions...To view the full article, register now.
Already a subscriber? Click here to view full article